Log in

Voyager Therapeutics Stock Forecast, Price & News

+0.89 (+8.30 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $11.61
50-Day Range
MA: $11.20
52-Week Range
Now: $11.61
Volume1.26 million shs
Average Volume332,824 shs
Market Capitalization$434.57 million
P/E RatioN/A
Dividend YieldN/A
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Voyager Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:VYGR



Sales & Book Value

Annual Sales$104.39 million
Book Value$2.68 per share


Net Income$-43,600,000.00


Market Cap$434.57 million
Next Earnings Date11/4/2020 (Estimated)
+0.89 (+8.30 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VYGR stock has increased by 23.1% and is now trading at $11.61.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Voyager Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Voyager Therapeutics

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Voyager Therapeutics

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.52. The business earned $28.68 million during the quarter, compared to analysts' expectations of $16.19 million. Voyager Therapeutics had a negative return on equity of 66.46% and a negative net margin of 60.61%.
View Voyager Therapeutics' earnings history

What price target have analysts set for VYGR?

10 brokers have issued twelve-month target prices for Voyager Therapeutics' stock. Their forecasts range from $13.00 to $26.00. On average, they anticipate Voyager Therapeutics' share price to reach $17.78 in the next twelve months. This suggests a possible upside of 53.1% from the stock's current price.
View analysts' price targets for Voyager Therapeutics

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 2,270,000 shares, a drop of 18.3% from the July 30th total of 2,780,000 shares. Based on an average trading volume of 316,300 shares, the short-interest ratio is currently 7.2 days. Currently, 9.5% of the company's stock are short sold.
View Voyager Therapeutics' Short Interest

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), Regenxbio (RGNX), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Crispr Therapeutics (CRSP), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO) and AbbVie (ABBV).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (7.25%), Vanguard Group Inc. (6.07%), Bank of New York Mellon Corp (3.02%), Nuveen Asset Management LLC (1.09%), Goldman Sachs Group Inc. (0.98%) and Federated Hermes Inc. (0.70%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Matthew P Ottmer, Neurocrine Biosciences Inc, Omar Khwaja and Robert W Hesslein.
View institutional ownership trends for Voyager Therapeutics

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Marshall Wace LLP, Algert Global LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Trexquant Investment LP, and Alps Advisors Inc.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, Matthew P Ottmer, Omar Khwaja, and Robert W Hesslein.
View insider buying and selling activity for Voyager Therapeutics

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Bank of Montreal Can, Jacobs Levy Equity Management Inc., PDT Partners LLC, Alberta Investment Management Corp, Rafferty Asset Management LLC, Cornerstone Investment Partners LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Voyager Therapeutics

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $11.61.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $434.57 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.